Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid.

Similar presentations


Presentation on theme: "Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid."— Presentation transcript:

1 Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia  Giulia Fontanelli, Melania Rocco, Francesco Caracciolo, Edoardo Benedetti, Gabriele Buda, Enrico Orciuolo, Giovanni Carulli, Sara Galimberti, Antonio Azzarà, Mario Petrini  Clinical Lymphoma, Myeloma and Leukemia  Volume 14, Issue 1, Pages e13-e17 (February 2014) DOI: /j.clml Copyright © 2014 Elsevier Inc. Terms and Conditions

2 Figure 1 FLT3 ITD Mutation in Patient 2. (A) Before Sorafenib Treatment; (B) After Sorafenib Treatment. The Peak at 428 Represents the Wild Type FLT3; the Peak at 437 Represents the ITD Allele Abbreviations: bp = base pair; FLT = fms-related tyrosine kinase; ITD = internal tandem duplication. Clinical Lymphoma, Myeloma and Leukemia  , e13-e17DOI: ( /j.clml ) Copyright © 2014 Elsevier Inc. Terms and Conditions


Download ppt "Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid."

Similar presentations


Ads by Google